Product
Supplier
Encyclopedia
Inquiry
Home > Encyclopedia > Erythromycin, cyclic 11,12-carbonate

Erythromycin, cyclic 11,12-carbonate

pharmaceutical raw materials
Erythromycin, cyclic 11,12-carbonate structure

Erythromycin, cyclic 11,12-carbonate 

structure
  • CAS No:

    55224-05-0

  • Formula:

    C38H65NO14

  • Chemical Name:

    Erythromycin, cyclic 11,12-carbonate

  • Synonyms:

    Erythromycin,cyclic 11,12-carbonate;4H-1,3-Dioxolo[4,5-c]oxacyclotetradecin,erythromycin deriv.;Erythromycin A 11,12-carbonate;Davercin;Erythromycin A cyclic 11,12-carbonate;Erythromycin cyclic carbonate;11054-95-8;54365-46-7;58117-63-8;67186-98-5

Description

Erythromycin Cyclocarbonate, derivative of Erythromycin, which is active against Gram-positive and some Gram-negative microorganisms.

Erythromycin, cyclic 11,12-carbonate Basic Attributes

759.92

759.92

Characteristics

189

1.22 g/cm3

859.8°C at 760 mmHg

1.534

LD50 oral in rat: 5800mg/kg

Erythromycin, cyclic 11,12-carbonate Use and Manufacturing

Davercin (erythromycin A cyclic 11,12-carbonate) is a first generation semi-synthetic erythromycin. Davercin is prepared by coupling the 11- and 12-OH groups to form a cyclic carbonate. This simple modification improves the stability and hydrophobicity of the macrocyclic structure. Davercin shows comparable or better in vitro potency, low host toxicity and improved pharmacokinetics compared with erythromycin.

Drug Function and Efficacy

It belongs to the macrolide antibiotics. It acts on the 50S subunit of bacterial cell ribosomes and inhibits the synthesis of bacterial proteins. Cyclic erythromycin is a semi-synthetic derivative of erythromycin. The introduction of cyclic carbonate groups greatly improves the lipophilicity of erythromycin, thereby increasing its absorption. This structural change reduces the serum protein binding rate, improves the antibacterial activity and reduces toxicity.

This ingredient has been used in drugs with the following functions (note: it does not mean that the ingredient itself has the following health functions)

Related Drugs

Registered Holders

  • Bright Future Pharmaceutical(Hainan) Co., Ltd.

    China China
    Active
  • Weizhi Pharmaceutical Co., Ltd.

    China China
    Inactive
  • China Resources Double-Crane Pharmaceutical Co., Ltd.

    China China
    Inactive

Scan the QR Code to Share

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.